作者
Robert G Feldman, Raffaele Antonelli-Incalzi, Katie Steenackers, Dong-Gun Lee, Alberto Papi, Michael G Ison, Laurence Fissette, Marie-Pierre David, Céline Maréchal, Marie Van der Wielen, Lusine Kostanyan, Veronica Hulstrøm
发表日期
2024/1/15
期刊
Clinical Infectious Diseases
卷号
78
期号
1
页码范围
202-209
出版商
Oxford University Press
简介
Background
Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, and RSV-ARI. We evaluated efficacy and immunogenicity among participants with coexisting cardiorespiratory or endocrine/metabolic conditions that increase the risk of severe RSV disease (“conditions of interest”).
Methods
Medically stable ≥60-year-old participants received 1 dose of RSVPreF3 OA or placebo. Efficacy against first RSV-LRTD and RSV-ARI episodes was …
学术搜索中的文章
RG Feldman, R Antonelli-Incalzi, K Steenackers… - Clinical Infectious Diseases, 2024